CDK4 and non-small cell lung carcinoma: Beyond breast cancer, a promising role for CDK4/6 inhibitors has also been observed in other malignancies, including NSCLC, glioblastoma (GBM), melanoma, and colorectal and ovarian cancers,39,40 which suggests their potential efficacy across multiple tumor types.